Obesity can be a chronic, relapsing disease
With retatrutide approaching ~30% weight loss at 2 yearsbut with what appears to be a meaningfully higher adverse event burden than earlier-generation incretin therapiesexpert clinical guidance will matter even more
Heart disease Diabetes Heart attack Fatty liver disease Cancer Less stress on your joints & organs Easier breathing Better sleep More energy Manage Your Weight If your BMI is 30 or higher, losing just 3% to 5% of your total weight is enough to start to see positive health changes
Additionally, if OCSCs are exposed to inflammatory mediators, undergo mesenchymal endothelial transformation, or experience dysregulation of the redox balance in the tumor microenvironment (TME), they may stimulate the continuous proliferation of OCSCs, potentially leading to OC development (63)
BPC-157 may be less appropriate for those with a history of cancer or active malignancy, individuals uncomfortable with the investigational nature of peptide therapy, people unable to commit to consistent daily administration for 4-8 weeks, those seeking instant results rather than gradual healing, and anyone who cannot source pharmaceutical-grade products from reputable suppliers
Thankyou Dr Niketa